News

Pharma update: injunction against generic combination of ezetimibe and simvastatin denied

In the interim relief decision of 11 June 2018 (ECLI:NL:RBDHA:2018:6802) in the matter Merck Sharp & Dohme Corp. / Teva Nederland B.V, Pharmachemie B.V. and Centrafarm B.V. the Provisions Judge of the District Court of The Hague rejected the claim of Merck Sharp & Dohme Corp. for an injunction against the distribution of the generic combination
Read more ›

Honourable mentions for BarentsKrans in the Legal 500

This week Legal 500 released their 2018 rankings. As in previous years, BarentsKrans is mentioned several times in this leading, international guide for the legal profession. Again we are beyond proud of these honourable mentions. High performers BarentsKrans is mentioned at nine different practice areas. Employment, Corporate/M&A, EU & Competition, Private equity, Real estate, Commercial Litigation,
Read more ›

Chambers Europe 2018 rankings: again splendid results for BarentsKrans

Last month we published the stunning results that BarentsKrans achieved in the Chambers 2018 Global edition. Meanwhile, the Chambers Europe guide has also been published and we would, once again, like to share our Chambers feedback with you. Chambers and Partners publish their rankings annually while comparing 53 jurisdictions across Europe, from Greenland and the United Kingdom to
Read more ›

Chambers Global 2018 rankings: excellent results for BarentsKrans

Chambers Global 2018, the guide that provides a worldwide overview of international practice areas, has just been released. BarentsKrans received several honourable mentions. This year the most noticeable mention is the Corporate / M&A practice group’s first ranking within the Mid-Markets category. Like last year, the Intellectual Property team has been rewarded with a splendid
Read more ›

Pharma update: Indirect infringement of Swiss type claims is possible

In its judgment of 3 November 2017 in the case between Merck Sharp & Dohme (‘MSD’) and Teva, the Dutch Supreme Court ruled (ECLI:NL:HR:2017:2807) that indirect infringement of a ‘Swiss type’ second medical use patent claim is possible. In addition, the Supreme Court found that there is no difference in the scope of protection of second
Read more ›

Pharma update: long-awaited final relief judgment on enforcement second medical use patent

In its final relief judgement of 5 April 2017 in Sun Pharmaceutical Industries (Europe) B.V. (“Sun“) v. Novartis et al. (“Novartis”), the District Court of The Hague ruled that Sun has directly infringed Novartis’ second medical use patent EP 1 296 689 (EP ‘689) which relates to the treatment of osteoporosis. Previously, in its interim
Read more ›